On March 5, 2023 Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, reported that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) special conference targeting RAS, held March 5-8, 2023, in Philadelphia (Press release, Immuneering, MAR 5, 2023, View Source [SID1234628145]). The data showed response to IMM-1-104 across a diverse panel of RAS mutant preclinical models regardless of mutation position or amino acid substitution, suggesting potential relevance to a broad RAS-driven patient population.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to share these preclinical data that support the universal-RAS activity of IMM-1-104 through its novel target engagement mechanism combined with deep cyclic inhibition. These results further demonstrate the rationale for the unique design of our Phase 1/2a clinical trial with IMM-1-104, which is enrolling patients with advanced solid tumors harboring RAS mutations," said Brett Hall, Ph.D., Chief Scientific Officer of Immuneering.

The poster presentation at AACR (Free AACR Whitepaper) special conference targeting RAS highlighted the following preclinical data:

Across all RAS-mutant models tested (132 tumor models, 75 of which have a reported RAS mutation), at least one model displayed response to IMM-1-104 for each observed RAS mutation, regardless of mutation position or amino acid substitution.
No significant preference was observed with respect to response to IMM-1-104 across 30 KRAS G12 mutated cell lines, the most commonly mutated position in KRAS, from three major cancer indications including pancreatic, lung and colorectal cancer models.
Title: Pan-RAS IMM-1-104 activity in humanized 3D tumor models is independent of specific amino acid substitution

Date: Tuesday, March 7, 2023, 4:45 – 7:00p.m. ET
Poster session: B
Abstract Number: B021